# Drug Trafficking: Stakeholders

The drug trafficking landscape is shaped by the interactions of several key groups, each with its own interests, power, and resources. Understanding these stakeholders -- from the criminal organizations that profit to the communities that suffer -- is essential to designing effective policy responses.

## Who Is Affected

### Primary Stakeholders

| Group | Impact | Size | Key Interests |
|-------|--------|------|---------------|
| People with substance use disorders | Direct consumers of trafficked drugs; face overdose risk, addiction, incarceration | 48.7 million (SAMHSA, 2024) | Access to treatment, harm reduction, decriminalization |
| Families of overdose victims | Grief, economic loss, trauma from losing family members to overdose | 107,543 deaths/year (2023); millions of family members affected | Accountability, prevention, access to naloxone |
| Border communities (U.S. side) | Violence spillover, enforcement disruption, stigmatization | ~7.5 million people in U.S. border counties | Safety, economic stability, reduced militarization |
| Mexican citizens in cartel-affected areas | Murder, extortion, displacement, corruption of governance | ~60 million in high-violence states | Safety, rule of law, economic opportunity |
| Incarcerated drug offenders | Loss of liberty, collateral consequences (employment, housing, family) | ~400,000 in U.S. prisons/jails for drug offenses (BJS, 2023) | Sentencing reform, reentry support, record expungement |
| Communities of color | Disproportionate enforcement, mass incarceration, family disruption | Millions; Black Americans 3.7x more likely to be arrested for drugs (ACLU, 2020) | Racial equity, enforcement reform, community investment |

### Secondary Stakeholders

- **Public health systems**: Emergency departments, treatment providers, and harm reduction organizations bear the costs of drug trafficking outcomes. U.S. hospitals spent an estimated $11.2 billion on opioid-related emergency care in 2023 (HCUP, 2024).
- **Rural communities**: Small towns in Appalachia, the Midwest, and the South face devastating opioid impacts with minimal treatment infrastructure. Some counties have lost 1-2% of their working-age population to overdose deaths.
- **U.S. taxpayers**: Bear the cost of the $46.1 billion annual federal drug control budget (FY2025) and hundreds of billions in indirect costs (lost productivity, healthcare, criminal justice).
- **Legitimate businesses**: Legal commerce is slowed by border inspection requirements; businesses in legal cannabis states face banking restrictions; chemical companies face regulatory scrutiny.
- **Latin American source and transit countries**: Colombia, Peru, Bolivia, Guatemala, Honduras, and El Salvador experience violence, corruption, and governance erosion from drug trafficking.

## Who Has Power

### Decision Makers

| Actor | Role | Authority | Resources | Influence Level |
|-------|------|-----------|-----------|-----------------|
| U.S. Congress | Legislation, appropriations, oversight | Drug scheduling, penalties, foreign aid, border funding | Control over $46.1 billion drug control budget | High |
| President / ONDCP | National drug control strategy, diplomatic leadership | Executive orders, agency coordination, diplomatic pressure | ONDCP budget $427 million (FY2025); bully pulpit | High |
| DEA Administrator | Drug enforcement strategy, scheduling recommendations | Investigation authority, foreign operations, scheduling | 10,800 personnel, $3.3 billion budget | High |
| CBP Commissioner | Border inspection and interdiction operations | Port of entry authority, between-port enforcement | 65,000 personnel, $19.8 billion budget | High |
| Treasury Secretary / FinCEN | Financial sanctions, anti-money laundering enforcement | OFAC sanctions, BSA enforcement, beneficial ownership | Sanctions authority; FinCEN 300+ staff | High |
| Attorney General / DOJ | Federal prosecution, policy guidance | Prosecution discretion, sentencing guidance | 115,000+ DOJ employees; $38 billion budget | High |
| Mexican President | Counter-narcotics policy, military deployment, cooperation | Sovereignty over Mexican territory and security forces | Mexican armed forces; federal police | High |
| Chinese government | Precursor chemical regulation and export controls | Authority over Chinese chemical industry | Regulatory authority over largest precursor source | High |

### Key Organizations and Institutions

- **Drug Enforcement Administration (DEA)**: The lead federal agency for drug enforcement with 5,000+ special agents, 92 foreign offices in 69 countries, and primary responsibility for investigating drug trafficking organizations. The DEA's institutional culture strongly favors enforcement over demand reduction.
- **Customs and Border Protection (CBP)**: The nation's largest law enforcement agency with ~65,000 employees responsible for inspecting all goods and people entering the United States. CBP is the frontline of interdiction at ports of entry.
- **U.S. Coast Guard**: Conducts maritime interdiction in the Eastern Pacific and Caribbean, intercepting cocaine-laden vessels. In FY2023, the Coast Guard seized 134,000 lbs of cocaine worth an estimated $1.9 billion.
- **Financial Crimes Enforcement Network (FinCEN)**: Treasury bureau responsible for analyzing suspicious activity reports and enforcing the Bank Secrecy Act. Chronically understaffed relative to the volume of financial intelligence it receives.
- **State Department Bureau of International Narcotics and Law Enforcement (INL)**: Manages U.S. international counter-narcotics programs with a $1.5 billion annual budget, including assistance to Mexico, Colombia, and Central America.
- **Joint Interagency Task Force South (JIATF-S)**: DoD-led joint task force in Key West, FL that coordinates maritime and aerial counter-narcotics detection and monitoring in the Western Hemisphere.

### Influencers

- **Drug trafficking organizations**: Cartels shape the trafficking landscape through their operational decisions, violence, corruption, and adaptation to enforcement. They wield enormous influence despite having no legitimate political standing.
- **Pharmaceutical industry**: Companies like Purdue Pharma (now bankrupt) and distributors like McKesson, Cardinal Health, and AmerisourceBergen created the opioid demand that fuels fentanyl trafficking. The industry retains significant lobbying power ($374 million in lobbying spending in 2023, OpenSecrets).
- **Law enforcement unions and associations**: The Fraternal Order of Police, National Sheriffs' Association, and similar organizations advocate for enforcement-heavy approaches and oppose decriminalization.
- **Think tanks and research organizations**: RAND Corporation, Brookings Institution, Cato Institute, and others produce research that shapes the policy debate. RAND's work on the cost-effectiveness of demand reduction has been particularly influential.
- **Advocacy organizations**: Drug Policy Alliance, Harm Reduction Coalition, and Families Against Fentanyl advocate for different reform approaches from decriminalization to harsher penalties.
- **Media**: Coverage of drug trafficking shapes public perception and political incentives. Sensationalized coverage of border drug seizures can increase support for enforcement, while reporting on overdose deaths may build support for treatment.

## Stakeholder Interests and Alignment

### Aligned Interests (Potential Coalition Partners)

| Coalition | Shared Interest | Strength |
|-----------|-----------------|----------|
| Public health organizations, treatment providers, harm reduction advocates | Expanding demand reduction funding, reducing overdose deaths | Strong -- united on outcomes, differ on methods |
| Fiscal conservatives, libertarians, sentencing reform advocates | Reducing wasteful spending on ineffective enforcement, ending mass incarceration | Moderate -- Right on Crime coalition has demonstrated bipartisan potential |
| Border communities, trade associations, CBP | Smarter inspection technology that improves security without slowing trade | Strong -- aligned economic and security interests |
| Families of overdose victims, public health officials, some law enforcement | Holding pharmaceutical companies accountable for the opioid crisis | Strong -- broad public support |
| Anti-corruption advocates, financial regulators, AML compliance industry | Strengthening anti-money laundering enforcement and beneficial ownership transparency | Moderate -- aligned on goals but banking industry resists cost increases |

### Conflicting Interests

- **DEA/enforcement agencies vs. public health advocates**: DEA prioritizes supply disruption and scheduling enforcement; public health advocates prioritize treatment access and harm reduction. DEA has historically opposed expanding medication-assisted treatment access and syringe services.
- **Mexican sovereignty vs. U.S. enforcement demands**: The U.S. seeks expanded joint operations, extraditions, and military cooperation; Mexico asserts sovereignty and resists what it views as interventionism. The Calderon-era military approach caused enormous civilian casualties.
- **Trade efficiency vs. border security**: Business interests want fast border crossings to support $800+ billion in annual U.S.-Mexico trade; security interests want thorough inspection. Scanning 100% of commercial vehicles would add hours to border crossing times.
- **Banking industry vs. financial transparency**: Banks earn fees from processing all transactions, including illicit ones, and resist the compliance costs of stronger AML requirements. FinCEN and regulators seek greater transparency and reporting.
- **Criminal justice establishment vs. decriminalization advocates**: Prosecutors, police unions, and private prison operators benefit from drug criminalization; decriminalization advocates seek to redirect resources from enforcement to treatment.

### The Iron Triangle of Drug Enforcement

The drug enforcement establishment functions as a self-reinforcing system:

1. **Congress** appropriates billions for enforcement agencies and receives campaign contributions from law enforcement unions and defense contractors
2. **Enforcement agencies** (DEA, CBP, DoD) use appropriations to conduct operations and lobby Congress for increased funding by highlighting seizures and arrests
3. **Defense and surveillance contractors** receive billions in border security contracts and lobby Congress and agencies for continued and expanded procurement

This triangle perpetuates enforcement-heavy approaches regardless of their effectiveness because all three parties benefit from the status quo.

## Influence Mechanisms

How stakeholders exert influence on drug trafficking policy:

- **Lobbying**: The pharmaceutical industry spent $374 million on lobbying in 2023 (OpenSecrets). Law enforcement organizations, defense contractors, and private prison companies also maintain active lobbying operations. The GEO Group and CoreCivic spent a combined $4.3 million on lobbying in 2023.
- **Campaign Contributions**: Law enforcement PACs, defense contractor PACs, and pharmaceutical company PACs collectively contribute tens of millions to congressional candidates. Members of the Senate and House Judiciary, Homeland Security, and Armed Services committees receive disproportionate contributions.
- **Revolving Door**: Former DEA administrators, CBP commissioners, and senior DOJ officials frequently move to private sector positions in defense contracting, consulting, and lobbying firms, maintaining influence over policy they previously directed.
- **Public Advocacy**: Families Against Fentanyl and similar groups have mobilized public opinion around the fentanyl crisis, pressuring Congress to classify fentanyl as a weapon of mass destruction. Drug Policy Alliance and reform organizations advocate through media, public education, and grassroots organizing.
- **Expertise/Information**: The DEA controls most intelligence on trafficking organizations and uses its information advantage to shape policy debates. Independent researchers at RAND, Brookings, and universities provide alternative analysis but lack the DEA's institutional access.

---

## Document Navigation

- Up: [Drug Policy Overview](../01-overview.md)
- Previous: [Root Causes](04-root-causes.md)
- Next: [Opposition](06-opposition.md)
